EpiPen maker Mylan to restructure and cut its workforce – STLtoday.com
Updated at 12:03 p.m. Generic drugmaker Mylan NV, which has been under fire for its price hikes on the life-saving EpiPen allergy treatment, said on Wednesday that it would restructure and expected to cut less than 10 percent of its global workforce as it integrates acquisitions. Mylan, whose shares were down more than 4 percent…